D Scott Lim1, Saibal Kar2, Konstantinos Spargias3, Robert M Kipperman4, William W O'Neill5, Martin K C Ng6, Neil P Fam7, Darren L Walters8, John G Webb9, Robert L Smith10, Michael J Rinaldi11, Azeem Latib12, Gideon N Cohen13, Ulrich Schäfer14, Leo Marcoff4, Prashanthi Vandrangi15, Patrick Verta15, Ted E Feldman16. 1. University of Virginia Health System Hospital, Charlottesville, Virginia. Electronic address: sl9pc@hscmail.mcc.virginia.edu. 2. Cedars-Sinai Medical Center, Los Angeles, California. 3. Hygeia Hospital, Athens, Greece. 4. Atlantic Health System Morristown Medical Center, Morristown, New Jersey. 5. Henry Ford Hospital, Detroit, Michigan. 6. Royal Prince Alfred Hospital, Camperdown, Australia. 7. St. Michael's Hospital, Toronto, Ontario, Canada. 8. The Prince Charles Hospital, Chermside, Australia. 9. St. Paul's Hospital, Vancouver, British Columbia, Canada. 10. The Heart Hospital Baylor Plano, Plano, Texas. 11. Sanger Heart & Vascular Institute, Charlotte, North Carolina. 12. San Raffaele Institute, Milan, Italy. 13. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 14. Marienkrankenhaus, Hamburg, Germany. 15. Edwards Lifesciences, Irvine, California. 16. Edwards Lifesciences, Irvine, California; NorthShore University Health System, Evanston Hospital, Evanston, Illinois.
Abstract
OBJECTIVES: The authors report the procedural and 30-day results of the PASCAL Transcatheter Valve Repair System (Edwards Lifesciences, Irvine, California) in patients with mitral regurgitation (MR) enrolled in the multicenter, prospective, single-arm CLASP study. BACKGROUND: Severe MR may lead to symptoms, impaired quality of life, and reduced functional capacity when untreated. METHODS: Eligible patients had grade 3+ or 4+ MR despite optimal medical therapy and were deemed appropriate for the study by the local heart team. All outcomes were assessed through 30 days post-procedure. Major adverse events (MAEs) were adjudicated by an independent clinical events committee, and echocardiographic images were assessed by a core laboratory. The primary safety endpoint was the rate of MAEs at 30 days. RESULTS: Between June 2017 and September 2018, 62 patients with grade 3+ or 4+ MR were enrolled. The mean age was 76.5 years, and 51.6% of patients were in New York Heart Association functional class III or IV, with 56% functional, 36% degenerative, and 8% mixed MR etiology. At 30 days, the MAE rate was 6.5%, with an all-cause mortality rate of 1.6% and no occurrence of stroke; 98% had MR grade ≤2+, with 86% with MR grade ≤1+ (p < 0.0001); and 85% were in New York Heart Association functional class I or II (p < 0.0001). Six-minute walk distance improved by 36 m (p = 0.0018), and Kansas City Cardiomyopathy Questionnaire and EQ-5D scores improved by 17 (p < 0.0001) and 10 (p = 0.0004) points, respectively. CONCLUSIONS: The PASCAL repair system showed feasibility and acceptable safety in the treatment of patients with grade 3+ or 4+ MR. MR severity, irrespective of etiology, was significantly reduced and accompanied by clinically and statistically significant improvements in functional status, exercise capacity, and quality of life. (The CLASP Study Edwards PASCAL Transcatheter Mitral Valve Repair System Study; NCT03170349).
OBJECTIVES: The authors report the procedural and 30-day results of the PASCAL Transcatheter Valve Repair System (Edwards Lifesciences, Irvine, California) in patients with mitral regurgitation (MR) enrolled in the multicenter, prospective, single-arm CLASP study. BACKGROUND: Severe MR may lead to symptoms, impaired quality of life, and reduced functional capacity when untreated. METHODS: Eligible patients had grade 3+ or 4+ MR despite optimal medical therapy and were deemed appropriate for the study by the local heart team. All outcomes were assessed through 30 days post-procedure. Major adverse events (MAEs) were adjudicated by an independent clinical events committee, and echocardiographic images were assessed by a core laboratory. The primary safety endpoint was the rate of MAEs at 30 days. RESULTS: Between June 2017 and September 2018, 62 patients with grade 3+ or 4+ MR were enrolled. The mean age was 76.5 years, and 51.6% of patients were in New York Heart Association functional class III or IV, with 56% functional, 36% degenerative, and 8% mixed MR etiology. At 30 days, the MAE rate was 6.5%, with an all-cause mortality rate of 1.6% and no occurrence of stroke; 98% had MR grade ≤2+, with 86% with MR grade ≤1+ (p < 0.0001); and 85% were in New York Heart Association functional class I or II (p < 0.0001). Six-minute walk distance improved by 36 m (p = 0.0018), and Kansas City Cardiomyopathy Questionnaire and EQ-5D scores improved by 17 (p < 0.0001) and 10 (p = 0.0004) points, respectively. CONCLUSIONS: The PASCAL repair system showed feasibility and acceptable safety in the treatment of patients with grade 3+ or 4+ MR. MR severity, irrespective of etiology, was significantly reduced and accompanied by clinically and statistically significant improvements in functional status, exercise capacity, and quality of life. (The CLASP Study Edwards PASCAL Transcatheter Mitral Valve Repair System Study; NCT03170349).
Authors: Steffen D Kriechbaum; Niklas F Boeder; Luise Gaede; Martin Arnold; Ursula Vigelius-Rauch; Peter Roth; Michael Sander; Andreas Böning; Matthias Bayer; Albrecht Elsässer; Helge Möllmann; Christian W Hamm; Holger M Nef Journal: Clin Res Cardiol Date: 2019-08-26 Impact factor: 5.460
Authors: Mirjam G Winkel; Nicolas Brugger; Omar K Khalique; Christoph Gräni; Adrian Huber; Thomas Pilgrim; Michael Billinger; Stephan Windecker; Rebecca T Hahn; Fabien Praz Journal: Front Cardiovasc Med Date: 2020-05-05
Authors: Faisal Khan; Mirjam Winkel; Geraldine Ong; Nicolas Brugger; Thomas Pilgrim; Stephan Windecker; Fabien Praz; Neil Fam Journal: Front Cardiovasc Med Date: 2019-09-18
Authors: Mohammed Al-Hijji; Abdallah El Sabbagh; Erin A Fender; Jeremy Thaden; Charanjit S Rihal; Mackram F Eleid Journal: Heart Views Date: 2020-01-23
Authors: Hector Cubero-Gallego; Daniel Hernandez-Vaquero; Pablo Avanzas; Marcel Almendarez; Antonio Adeba; Rebeca Lorca; Jose Rozado; Alain Escalera; Jacobo Silva; Cesar Moris; Isaac Pascual Journal: Ann Transl Med Date: 2020-08